Sign In

Paul Y. Song, MD

Chief Executive Officer at NKGen Biotech, Inc.

Paul Y. Song, MD

Paul Y. Song, MD is the Chief Executive Officer and Chairman at NKGen Biotech, Inc. He has over 30 years of experience in the biotechnology and medical industry, with a focus on oncology, immunology, and therapeutic development.1

Key Positions

  • Chief Executive Officer and Chairman, NKGen Biotech, Inc. (January 2023 - Present)1
  • Vice Chairman of the Board, NKGen Biotech, Inc. (December 2021 - Present)1
  • Co-Founder & CEO, Fuse Biotherapeutics (July 2021 - January 2023)1
  • Chief Medical Advisor, Hawkeye Bio, Inc. (July 2017 - Present)1

Education and Training

  • BA with honors, Biological Sciences, University of Chicago (1983 - 1987)1
  • MD, The George Washington University School of Medicine and Health Sciences (1987 - 1991)1
  • Chief Resident '95, Radiation and Cellular Oncology, The University of Chicago Pritzker School of Medicine (1992 - 1995)1
  • ASTRO Research Fellow - Dept. of Radiation and Cellular Oncology, The University of Chicago Pritzker School of Medicine (1995 - 1996)1

Expertise

  • Board Certified Radiation Oncologist1
  • Skilled in Management, Translational Medicine, Clinical Trials, Regulatory Affairs, Medical Devices, Diagnostics, Governmental Affairs, and Healthcare Policy1

Dr. Song is a prominent figure in the biotech industry and has been actively involved in the fight against COVID-19, advocating for mask-wearing and raising awareness about the seriousness of the virus.2 His LinkedIn username is paul-y-song-md-7664147.1

Highlights

Jul 30 · linkedin

As more data emerges on how high levels of α-synuclein in Alzheimer’s disease are correlated with disease progression and worsened cognitive function, we are pleased to present our data showing SNK01’s ability to reduce α-synuclein and improve cognitive function.

Jul 30 · linkedin

Proud to present our latest data at #AAIC24 showing that our enhanced SNK01 natural killer cells are very safe and can cross the blood brain barrier to reduce α-synuclein proteins and improve cognitive function in Alzheimer’s patients. Emerging evidence suggests that α-synuclein is associated with a worse clinical presentation and no current therapeutic for Alzheimer’s addresses this. While we have previously shown that SNK01 can improve CSF levels of amyloid and tau proteins as well as reduce neuroinflammation caused by auto-reactive T cells, being able to show real in-human activity against α-synuclein provides yet another potential way SNK01 can work against not only Alzheimer’s, but also in Parkinson’s and Lewy Body Dementia which are primarily attributed to α-synucleinapathy. #aaic24 #alzheimers #αsynuclein #parkinsons #lewybodydementia #neuroinflammation #nkcells #nkgenbiotech #snk01

Related Questions

What are Paul Y. Song's key achievements at NKGen Biotech, Inc?
How did Paul Y. Song transition from being a radiation oncologist to a biotech CEO?
What is the focus of NKGen Biotech, Inc. under Paul Y. Song's leadership?
What are some notable projects Paul Y. Song has worked on at Fuse Biotherapeutics?
How has Paul Y. Song's experience as a radiation oncologist influenced his approach in biotech?
Paul Y. Song, MD
Paul Y. Song, MD, photo 1
Paul Y. Song, MD, photo 2
Add to my network

Experience

Chief Executive Officer at NKGen Biotech, Inc. since January 2023
Vice Chairman of the Board at NKGen Biotech, Inc. (Dec 2021 - Present); Co-Founder & Senior Advisor at Fuse Biotherapeutics (Jan 2023 - Present); Co-Founder & CEO at Fuse Biotherapeutics (Jul 2021 - J at Calyx Peak (Apr 2017 - Present)

Education

MD in Medicine from The George Washington University School of Medicine and Health Sciences (1987-1991); Chief Resident in Radiation and Cellular Oncology at The University of Chicago Pritzker School

Location

Los Angeles Metropolitan Area